You are here

  • Home
  • Archive
  • Volume 71, Issue 11
  • Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials

Citation Tools

Article menu

Download PDFPDF

Clinical and epidemiological research
Extended report
Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Manzi S, Sánchez-Guerrero J, Merrill JT on behalf of the BLISS-52 and BLISS-76 Study Groups, et al
Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials
Annals of the Rheumatic Diseases 2012;71:1833-1838.